Ani Pharmaceuticals (ANIP) Gains from Investment Securities (2010 - 2026)

Ani Pharmaceuticals has disclosed Gains from Investment Securities across 16 years of filings, most recently posting -$6.1 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$6.1 million, down 2228.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $291000.0 (up 105.75% YoY), and the FY2025 annual result was $6.6 million, changed N/A from the prior year.
• Gains from Investment Securities came in at -$6.1 million for Q1 2026 at Ani Pharmaceuticals, down from $6.9 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $6.9 million in Q4 2025 to a low of -$6.1 million in Q1 2026.
• The 4-year median for Gains from Investment Securities is $242500.0 (2022), against an average of $400500.0.
• Across the five-year window, Gains from Investment Securities soared 3959.02% in 2022 and tumbled 2228.07% in 2026, its largest moves.
• Ani Pharmaceuticals' Gains from Investment Securities stood at $2.5 million in 2022, then sank by 315.95% to -$5.3 million in 2024, then soared by 229.72% to $6.9 million in 2025, then plunged by 187.44% to -$6.1 million in 2026.
• The last three Gains from Investment Securities figures came in at -$6.1 million (Q1 2026), $6.9 million (Q4 2025), and -$295000.0 (Q3 2025), per Business Quant data.